Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Jul 2020

Han Sen, Ma Xu, Fang Jian

Abstract excerpt

Mesenchymal-epithelial transition factor (MET) gene is an important tumor driver gene of non-small cell lung cancer (NSCLC). Drugs targeting MET 14 exon skipping mutation bring new hope to patients. MET inhibitors that are currently on the market or are about to be marketed include: crizotinib, cabozantinib, savolitinib and tepotinib. The objective response rate of MET inhibitors is high, and the safety is good....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins c-met

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 32702795
DOI: 10.3779/j.issn.1009-3419.2020.102.32
PMCID: PMC7406436

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].PMID 32702795Read ↗

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Semantic proximity Read ↗

[Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].Semantic proximity Read ↗

[Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation].Semantic proximity Read ↗

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity Read ↗

[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

[Current Status and Prospect of T790M Mutation in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Progress on treatment of MET signaling pathway in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.